The estimated Net Worth of J David Jr Enloe is at least $1.35 Milion dollars as of 15 March 2022. Mr Enloe owns over 512 units of Recro Pharma Inc stock worth over $1,096,997 and over the last 4 years he sold REPH stock worth over $0. In addition, he makes $255,526 as Pres i CEO & Director at Recro Pharma Inc.
Mr has made over 5 trades of the Recro Pharma Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 512 units of REPH stock worth $1,004 on 15 March 2022.
The largest trade he's ever made was buying 1,725 units of Recro Pharma Inc stock on 12 November 2021 worth over $2,898. On average, Mr trades about 575 units every 18 days since 2020. As of 15 March 2022 he still owns at least 524,879 units of Recro Pharma Inc stock.
You can see the complete history of Mr Enloe stock trades at the bottom of the page.
J. David Enloe Jr. is the Pres, CEO & Director at Recro Pharma Inc.
As the Pres i CEO & Director of Recro Pharma Inc, the total compensation of Mr Jr at Recro Pharma Inc is $255,526. There are 8 executives at Recro Pharma Inc getting paid more, with Geraldine Henwood having the highest compensation of $4,622,980.
Mr Jr is 57, he's been the Pres i CEO & Director of Recro Pharma Inc since . There are 5 older and 4 younger executives at Recro Pharma Inc. The oldest executive at Recro Pharma Inc is Winston Churchill, 79, who is the Independent Director.
J's mailing address filed with the SEC is C/O RECRO PHARMA, INC., 1 E. UWCHLAN AVE, SUITE 112, EXTON, PA, 19341.
Over the last 11 years, insiders at Recro Pharma Inc have traded over $25,533,136 worth of Recro Pharma Inc stock and bought 3,055,820 units worth $22,429,197 . The most active insiders traders include Healthcare Master Fund Ltd ..., Investment Company, Inc. Awm oraz James E Deerfield Mgmt L.P..... On average, Recro Pharma Inc executives and independent directors trade stock every 31 days with the average trade being worth of $151,953. The most recent stock trade was executed by J David Jr Enloe on 15 March 2022, trading 512 units of REPH stock currently worth $1,004.
Recro Pharma Inc. is a contract development and manufacturing organization (CDMO) with capabilities from early feasibility to commercial manufacturing. With an expertise in solving complex manufacturing problems, Recro is a leading CDMO providing oral solid dosage form development, end-to-end regulatory support, clinical and commercial manufacturing, and packaging and logistics services to the global pharmaceutical market.
Recro Pharma Inc executives and other stock owners filed with the SEC include: